Dipeptidyl Peptidase IV and Its Inhibitors: Therapeutics for Type 2 Diabetes and What Else?

2013 ◽  
Vol 57 (6) ◽  
pp. 2197-2212 ◽  
Author(s):  
Lucienne Juillerat-Jeanneret
Keyword(s):  
Type 2 Diabetes ◽  
Dipeptidyl Peptidase ◽  
Dipeptidyl Peptidase Iv

Association between HbA1c and dipeptidyl peptidase IV activity in type 2 diabetes mellitus

2012 ◽  
Vol 413 (11-12) ◽  
pp. 1020-1021 ◽  
Author(s):  
Luziane Potrich Bellé ◽  
Paula Eliete Rodrigues Bitencourt ◽  
Karine Santos De Bona ◽  
Rafael Noal Moresco ◽  
Maria Beatriz Moretto
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Dipeptidyl Peptidase ◽  
Dipeptidyl Peptidase Iv

Inhibition of dipeptidyl peptidase IV activity as a therapy of Type 2 diabetes

2006 ◽  
Vol 11 (3) ◽  
pp. 525-539 ◽  
Author(s):  
Brian D Green ◽  
Peter R Flatt ◽  
Clifford J Bailey
Keyword(s):  
Type 2 Diabetes ◽  
Dipeptidyl Peptidase ◽  
Dipeptidyl Peptidase Iv

scholarly journals Risk of Dementia in Older Patients with Type 2 Diabetes on Dipeptidyl-Peptidase IV Inhibitors Versus Sulfonylureas: A Real-World Population-Based Cohort Study

2018 ◽  
Vol 8 (1) ◽  
pp. 28 ◽  
Author(s):  
Young-Gun Kim ◽  
Ja Jeon ◽  
Hae Kim ◽  
Dae Kim ◽  
Kwan-Woo Lee ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Propensity Score ◽  
Elderly Patients ◽  
Propensity Score Matching ◽  
Real World ◽  
Lower Risk ◽  
Dipeptidyl Peptidase ◽  
Dipeptidyl Peptidase Iv ◽  
Dipeptidyl Peptidase Iv Inhibitors

Background: Type 2 diabetes is related to an increased risk of dementia. Preclinical studies of dipeptidyl peptidase-IV inhibitors (DPP-4i) for dementia have yielded promising results. Therefore, we investigated the risk of dementia in elderly patients with type 2 diabetes on DPP-4is and sulfonylureas (SU). Methods: Using a claims database called the Korean National Health Insurance Service Senior cohort, new users of DPP-4is and SUs were matched by 1:1 propensity score matching using 49 confounding variables (7552 new DPP-4is users and 7552 new SU users were matched by 1:1 propensity score matching; average age 75.4; mean follow-up period: 1361.9 days). Survival analysis was performed to estimate the risk of dementia. Results: The risk of all-cause dementia was lower in the DPP-4i group compared to the SU group (hazard ratio (HR) 0.66; 95% confidence interval (CI) 0.56–0.78; p < 0.001). Particularly, DPP-4i use showed a significantly lower risk of Alzheimer’s disease (HR 0.64; 95% CI 0.52–0.79; p < 0.001) and a lower risk, albeit non-significant, of vascular dementia compared to SU use (HR 0.66; 95% CI 0.38–1.14; p = 0.139). Conclusion: Our findings suggest that DPP-4i use decreases the risk of dementia compared to SU use in elderly patients with type 2 diabetes in a real-world clinical setting.

Discovery and Preclinical Profile of Saxagliptin (BMS-477118):  A Highly Potent, Long-Acting, Orally Active Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes

2005 ◽  
Vol 48 (15) ◽  
pp. 5025-5037 ◽  
Author(s):  
David J. Augeri ◽  
Jeffrey A. Robl ◽  
David A. Betebenner ◽  
David R. Magnin ◽  
Ashish Khanna ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Dipeptidyl Peptidase ◽  
Dipeptidyl Peptidase Iv ◽  
Long Acting ◽  
Orally Active
Sign in / Sign up

Export Citation Format

Share Document